



## The Present and Future of Allergen Immunotherapy in Personalized Medicine

Guest Editor:

**Prof. Dr. Giorgio Walter  
Canonica**

1. Personalized Medicine, Asthma  
and Allergy-IRCCS Humanitas  
Research Hospital-Via Alessandro  
Manzoni, 56, 20089 Rozzano, Italy  
2. Department of Biomedical  
Sciences, Humanitas University,  
20090 Pieve Emanuele, Italy

Deadline for manuscript  
submissions:  
**closed (15 June 2023)**

### Message from the Guest Editor

Allergen immunotherapy is a medical treatment for allergies. It is a *disease-modifying therapy*, indicated for the treatment of allergic rhinitis, allergic conjunctivitis, allergic asthma, and Hymenoptera hypersensitivity. Allergen immunotherapy can be administered either subcutaneously in a physician's office or sublingually by a patient at home. Oral immunotherapy is used in food allergies. In addition, several biologics that control specific responsible molecules and directly suppress allergic reactions have recently become available. Even in the current era, the significance of allergen immunotherapy, which modifies the natural history of allergic diseases, seems to be prominent.

This Special Issue aims to highlight the role of personalized medicine in clinical practice, providing a complete overview of allergen immunotherapy and highlighting the critical issues in its management. We welcome the submission of original papers and reviews regarding allergen immunotherapy for allergic diseases.

Prof. Dr. Giorgio Walter Canonica  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)